In addition, through the inhibition of Lck and Fyn, TG02 reversed the BCR-mediated activation of NF-κB, SYK, and Akt, an action to abrogate the protection of CLL cells by the microenvironment. The gene discussed is NFKB1; the disease is B-cell chronic lymphocytic leukemia.